1. Home
  2. NDRA vs WINT Comparison

NDRA vs WINT Comparison

Compare NDRA & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NDRA
  • WINT
  • Stock Information
  • Founded
  • NDRA 2007
  • WINT 1992
  • Country
  • NDRA United States
  • WINT United States
  • Employees
  • NDRA N/A
  • WINT N/A
  • Industry
  • NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NDRA Health Care
  • WINT Health Care
  • Exchange
  • NDRA Nasdaq
  • WINT Nasdaq
  • Market Cap
  • NDRA 2.3M
  • WINT 2.2M
  • IPO Year
  • NDRA 2017
  • WINT 1995
  • Fundamental
  • Price
  • NDRA $3.58
  • WINT $0.43
  • Analyst Decision
  • NDRA Strong Buy
  • WINT Hold
  • Analyst Count
  • NDRA 1
  • WINT 1
  • Target Price
  • NDRA $46.00
  • WINT $350.00
  • AVG Volume (30 Days)
  • NDRA 32.0K
  • WINT 7.1M
  • Earning Date
  • NDRA 08-13-2025
  • WINT 08-18-2025
  • Dividend Yield
  • NDRA N/A
  • WINT N/A
  • EPS Growth
  • NDRA N/A
  • WINT N/A
  • EPS
  • NDRA N/A
  • WINT N/A
  • Revenue
  • NDRA N/A
  • WINT N/A
  • Revenue This Year
  • NDRA N/A
  • WINT N/A
  • Revenue Next Year
  • NDRA N/A
  • WINT N/A
  • P/E Ratio
  • NDRA N/A
  • WINT N/A
  • Revenue Growth
  • NDRA N/A
  • WINT N/A
  • 52 Week Low
  • NDRA $2.90
  • WINT $0.36
  • 52 Week High
  • NDRA $197.75
  • WINT $737.44
  • Technical
  • Relative Strength Index (RSI)
  • NDRA 51.99
  • WINT 35.91
  • Support Level
  • NDRA $3.14
  • WINT $0.52
  • Resistance Level
  • NDRA $3.60
  • WINT $0.64
  • Average True Range (ATR)
  • NDRA 0.20
  • WINT 0.09
  • MACD
  • NDRA 0.05
  • WINT -0.00
  • Stochastic Oscillator
  • NDRA 72.13
  • WINT 14.12

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Share on Social Networks: